Navigation Links
JDP Therapeutics, Inc. Appoints Christopher M. Cashman to Board of Directors
Date:6/18/2010

JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today the appointment of Christopher M. Cashman to its Board of Directors. Mr. Cashman has an impressive track record in heading start-up pharmaceutical companies and advancing them to exit in addition to having over 30 years of industry experience.

Lansdale, Pennsylvania (PRWEB) June 18, 2010 -- JDP Therapeutics, Inc., a specialty pharmaceutical company, announced today the appointment of Christopher M. Cashman to its Board of Directors. Mr. Cashman has an impressive track record in heading start-up pharmaceutical companies and advancing them to exit in addition to having over 30 years of industry experience.

"Chris has been an invaluable advisor to JDP since its inception working along side founder Jie Du, Ph.D. for the past two years. He has played an integral role in the company’s success to date and we are thrilled that Chris has decided to become a formal member of the team,” said Josh Tarnoff, JDP’s CEO and Executive Board Member. “On a personal note, he is highly respected and well known for his strong integrity and relationships in both the corporate and investment communities.”

Christopher Cashman is co-founder of Protez Pharmaceuticals Inc. and served as Director, President and CEO. Protez was acquired by Novartis in 2008. He was the recipient of the “Entrepreneur of the Year” award at the 2008 MAC Alliance Conference and the “Life Sciences CEO of the Year” by the Eastern Technology Council. He currently also serves on the Board of Directors of Noble Biomaterials, MBF Therapeutics and the Science Center.

“It has been a pleasure working with Jie on the start-up phase of JDP, and now with Josh on board as CEO, JDP is well positioned to advance JDP-205 into the clinic,” said Mr. Cashman.

Company founder Jie Du, Ph.D. added, “The timing for Chris to join our team is especially fitting as we are now poised to move our flagship product into Phase I clinical trial development. We are excited that he will continue to share in our growth and help guide the Board through this very important phase.”

JDP Therapeutics Inc., founded in 2008, is a specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for acute care use in the hospital setting.

For further information, please call 215-661-8557 or email info(at)jdptherapeutics(dot)com.

###

Read the full story at http://www.prweb.com/releases/JDP_Therapeutics/Pharmaceuticals/prweb4159384.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
2. Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast
3. EWI Worldwide Appoints Matt Hubbard President, Exhibit Works Division
4. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
5. Providence Hospital Appoints Four New Members to its Board of Directors
6. iSirona Appoints Chief Quality and Regulatory Officer to Oversee Quality Initiatives
7. Connectyx Technologies Holdings Group, Inc. Appoints Dr. James R. Taylor to Its Board of Advisors
8. Trinity Health Appoints Four to Board of Directors Trinity Health Appoints Four to Board of Directors
9. GeoVax Labs Appoints Two Industry Veterans to Board of Directors
10. Bon Secours Charity Health System Appoints Philip A. Patterson As CEO
11. Touro Appoints Alan Kadish, M.D. President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to the La Gorce Country Club in Miami Beach to host its Swirl: ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, SEO ... already in the state and in nearby New Hampshire, Massachusetts and Canada, Rosica ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only nursing quality ... conference – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. ... Mason Health System in Seattle since 2000. In addition to his role at Virginia ...
(Date:2/23/2017)... CHURCH, Va. (PRWEB) , ... February 23, 2017 , ... ... worries, or problems. He has also continued to spiritually evolve, which is the purpose ... published book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 ... Research and Markets has announced ... - Industry Forecast to 2025" report to their offering. ... CAGR of around 1.8% over the next decade to reach approximately $12.8 ... market estimates and forecasts for all the given segments on global as ...
(Date:2/23/2017)... MARIETTA, Ga., Feb. 23, 2017  MiMedx Group, Inc. ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of ... quarter and full year ended December 31, 2016. ... Revenue is a 31% increase over full year ...
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Medicine Technology: